Cascinu S, Del Ferro E, Barbanti I, Ligi M, Fedeli A, Catalano G
Servizio di Oncologia Medica, Ospedale di Pesaro, Italy.
Am J Clin Oncol. 1997 Jun;20(3):247-50. doi: 10.1097/00000421-199706000-00007.
To assess the possibility of increasing the detection rates of cytological examination in malignant effusions by the selection of specific tumor markers for a given type of tumor, we measured CEA, CA 19.9, CA 15.3, MCA, PSA, and AFP in malignant effusions from 89 patients with the following primary malignancies: colon, stomach, breast, liver, prostate, lung, and kidney. Cytological examination was positive in only 35 of 89 patients (40%), while the tumor markers were positive in 72 of 89 cases (80%). However, apart from small cell lung and kidney cancers, where the lack of a specific tumor marker resulted in no advantage, in the other types of tumors, the specific marker for each tumor identified correctly malignant effusions in 72 of 74 cases (97%). In fact, CEA was positive in 11 of 11 effusions induced by colorectal cancer; CA 19.9 in 28 of 30 gastric cancer effusions, while MCA and CA 15.3 were positive in breast cancer effusions (16/22 and 20/22). Finally, elevated AFP and PSA indicated hepatocellular and prostate cancer, respectively. In conclusion, in cancer patients with elevated effusion levels of specific tumor markers, the effusions could be considered of a malignant nature even without cytologically demonstrable tumor cells.
为了评估通过为特定类型肿瘤选择特异性肿瘤标志物来提高恶性胸腔积液细胞学检查检出率的可能性,我们检测了89例患有以下原发性恶性肿瘤(结肠癌、胃癌、乳腺癌、肝癌、前列腺癌、肺癌和肾癌)患者的恶性胸腔积液中的癌胚抗原(CEA)、糖类抗原19.9(CA 19.9)﹑糖类抗原15.3(CA 15.3)、巨唾液酸糖蛋白(MCA)、前列腺特异性抗原(PSA)和甲胎蛋白(AFP)。89例患者中只有35例(40%)细胞学检查呈阳性,而肿瘤标志物在89例中有72例(80%)呈阳性。然而,除了小细胞肺癌和肾癌缺乏特异性肿瘤标志物而无优势外,在其他类型肿瘤中,每种肿瘤的特异性标志物在74例中的72例(97%)中正确识别出恶性胸腔积液。事实上,11例结直肠癌引起的胸腔积液中有11例CEA呈阳性;30例胃癌胸腔积液中有28例CA 19.9呈阳性,而MCA和CA 15.3在乳腺癌胸腔积液中呈阳性(分别为16/22和20/22)。最后,AFP和PSA升高分别提示肝细胞癌和前列腺癌。总之,在肿瘤标志物胸腔积液水平升高的癌症患者中,即使没有细胞学可证实的肿瘤细胞,也可认为胸腔积液具有恶性性质。